Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084481 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
A Phase 1 study of Hepatocellular Carcinoma and Head and Neck Squamous Cell Carcinoma, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT06084481: Active Phase 1 study of Hepatocellular Carcinoma and Head and Neck Squamous Cell Carcinoma, sponsored by AbbVie.
NCT06084481 is a Phase 1 study of Hepatocellular Carcinoma and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 302 participants, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06084481, a Phase 1 study of Hepatocellular Carcinoma and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy) followed by a safety follow-up period. Cohort 9 receives ABBV-400 in combination with a strong CYP3A3 inhibitor (ITZ) followed by a safety follow-up period. Approximately 285 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive \[HR+\]/HER2-breast cancer \[BC\]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide. In cohorts 1-8, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy and in cohort 9 participants will receive intravenous (IV) ABBV-400 and an oral solution of ITZ, for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questi
Primary Outcome
ORR defined as percentage of participants with confirmed best overall response of confirmed partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Conditions Studied
Interventions
- DRUG ABBV-400
- DRUG Itraconazole (ITZ)
Study Locations (20)
Texas
- MD Anderson Cancer Center /ID# 255131 - Houston
- Univ Texas HSC San Antonio /ID# 257708 - San Antonio
- South Texas Accelerated Research Therapeutics /ID# 260404 - San Antonio
California
- City of Hope National Medical Center /ID# 258645 - Duarte
- Ucsf /Id# 257705 - San Francisco
Colorado
- University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128 - Aurora
- Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 - Denver
Illinois
- Northwestern University Feinberg School of Medicine /ID# 257378 - Chicago
- University of Chicago Medical Center /ID# 258197 - Chicago
South Carolina
- MUSC Hollings Cancer Center /ID# 257935 - Charleston
- Prisma Health /ID# 257697 - Greenville
Florida
- Florida Cancer Specialists /ID# 261569 - Sarasota
Michigan
- START Midwest /ID# 256581 - Grand Rapids
Missouri
- Washington University-School of Medicine /ID# 257379 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What the registry record for NCT06084481 still lists
NCT06084481 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (18% higher).
The record links to 8 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ABBV-400 is the first listed.
NCT06084481 names 20 study sites across 14 states, led by Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06084481 about?
NCT06084481 is a clinical study titled "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being...
What is the current status of trial NCT06084481?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 302 participants. The study started on 2023-11-09. Estimated completion is 2026-07.
What conditions does trial NCT06084481 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06084481?
The interventions under investigation include: ABBV-400 (DRUG), Itraconazole (ITZ) (DRUG).
Who is sponsoring clinical trial NCT06084481?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084481 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06084481's enrollment target sits among peer trials
302 37th of 145 higher than 109 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI